Table of Contents

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-122639

PROSPECTUS SUPPLEMENT

(To prospectus dated March 25, 2005)

$275,060,000

Merrill Lynch & Co., Inc.

6.75% Mandatorily Exchangeable Securities due October 15, 2007

Mandatorily Exchangeable for

Shares of Class A Common Stock of NUVEEN INVESTMENTS, INC.

The principal amount and issue price of each security is $34.00.

You should read the more detailed description of the securities in this prospectus supplement. In particular, you should review and understand the descriptions in “Summary of the Offering” and “Description of Securities.”

Investing in the securities involves risks that are described in the section entitled “ Risk Factors” beginning on page S-9.

This prospectus supplement and the accompanying prospectus are being used by Merrill Lynch, Pierce, Fenner & Smith Incorporated, our wholly owned subsidiary, and its affiliates in connection with offers and sales of the securities in market-making transactions at negotiated prices related to prevailing market prices at the time of sale or otherwise. Merrill Lynch, Pierce, Fenner & Smith Incorporated and its affiliates may act as principal or agent in such transactions. The securities were initially sold by us pursuant to a prospectus dated April 6, 2005.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus of ML&Co. is truthful or complete. Any representation to the contrary is a criminal offense.

Merrill Lynch & Co.

The date of this prospectus supplement is May 3, 2005.

Table of Contents

TABLE OF CONTENTS

Prospectus Supplement

S-2

Table of Contents

SUMMARY OF THE OFFERING

The following summary describes the securities we are offering to you in general terms only. The securities are a series of our debt securities described in our accompanying prospectus and referred to therein as Structured Yield Product Exchangeable for Stock^SM, or STRYPES^SM, and referred to herein as “securities.” You should read the summary together with the more detailed information that is contained in the rest of this prospectus supplement and in our accompanying prospectus. You should carefully consider, among other things, the matters set forth in “Risk Factors” in this prospectus supplement.

The securities offered are debt securities of ML&Co. The return on the securities at maturity will be based on the performance of the Class A common stock of Nuveen Investments, Inc., which we refer to as Nuveen Stock. We have included in this prospectus supplement certain limited information about Nuveen Investments, Inc., which we refer to as Nuveen. Information relating to Nuveen set forth herein was derived solely from publicly available documents filed by Nuveen with the SEC and from other publicly available information. We make no representation or warranty as to the accuracy or completeness of those reports or as to any of the information relating to Nuveen set forth herein.

References in this prospectus supplement to “ML&Co.,” “we,” “us” and “our” are to Merrill Lynch & Co., Inc., and references to “MLPF&S” are to Merrill Lynch, Pierce, Fenner & Smith Incorporated.

S-3

Table of Contents

Holders may receive at maturity an amount of cash, Nuveen Stock or a combination thereof.

S-4

Table of Contents

S-5

Table of Contents

S-6

Table of Contents

Concurrent Offerings

Concurrently with the initial offering of the securities, St. Paul Travelers offered to the public 39,309,155 shares of Nuveen Stock (43,240,071 shares if the underwriters were to have exercised an over-allotment option in full), representing approximately 42% of the outstanding shares of Nuveen Stock (approximately 46% if the over-allotment option were to have been exercised in full), which we refer to as the secondary offering. In addition, we understand that Morgan Stanley issued and sold, in a registered offering, $275,060,000 of its 5.875% Mandatorily Exchangeable Securities due October 15, 2008 that will be mandatorily exchangeable for between 6,741,397 and 8,090,000 shares of Nuveen Stock based on the closing price of Nuveen Stock over a thirty trading day period prior to the maturity of such mandatorily exchangeable debt securities.

In order to hedge, in part, our anticipated exposure in connection with the securities, a subsidiary of ours has entered into a forward sale agreement with St. Paul Travelers pursuant to which St. Paul Travelers will deliver, subject to St. Paul Travelers’ right to cash settle such forward sale agreement, 5,824,800 shares of Nuveen Stock. See “Use of Proceeds and Hedging” in this prospectus supplement. We understand that a subsidiary of Morgan Stanley has entered into a similar forward sale agreement with St. Paul Travelers with respect to 6,067,500 shares of Nuveen Stock.

Also concurrently with the initial offering of the securities, Nuveen purchased directly from St. Paul Travelers $600 million of shares of Nuveen Class B common stock at a price per share equal to the net proceeds per share that St. Paul Travelers received from the underwriters in the secondary offering mentioned above. Nuveen purchased $200 million of such shares on the closing date of the initial offering of the securities and has entered into a stock repurchase forward agreement with St. Paul Travelers under which Nuveen will repurchase directly from St. Paul Travelers $400 million of such shares.

Nuveen

Nuveen’s principal businesses are asset management and related research as well as the development, marketing and distribution of investment products and services for the affluent, high-net-worth and institutional market segments. Nuveen did not receive any of the proceeds from the original issuance of the securities and will not have any obligation under the securities.

All disclosures contained in this prospectus supplement regarding Nuveen are derived from the publicly available documents filed by Nuveen with the SEC and from other publicly available information. Neither ML&Co. nor MLPF&S has participated in the preparation of these documents or made any due diligence inquiry with respect to Nuveen in connection with the offering of the securities. Neither ML&Co. nor MLPF&S makes any representation that the publicly available documents or any other publicly available information regarding

S-7

Table of Contents

Nuveen are accurate or complete. Furthermore, there can be no assurance that all events occurring prior to the date hereof, including events that would affect the accuracy or completeness of the publicly available documents described above or that would affect the trading price of Nuveen Stock, have been publicly disclosed by Nuveen. Subsequent disclosure of any events or the disclosure of or failure to disclose material future events concerning Nuveen could affect the value of the Nuveen Stock to be received at maturity of the securities and therefore the trading prices of the securities. Neither ML&Co. nor any of its affiliates make any representation to any purchaser of the securities as to the performance of Nuveen Stock.

We and/or our affiliates may presently or from time to time engage in business with Nuveen, including extending loans to, or making equity investments in, Nuveen or providing advisory services to Nuveen, including merger and acquisition advisory services. In the course of such business, we and/or our affiliates may acquire non-public information with respect to Nuveen, and neither we nor any of our affiliates undertakes to disclose any such information to you. In addition, one or more of our affiliates may publish research reports with respect to Nuveen and the reports may or may not recommend that investors buy, hold or sell Nuveen Stock. As a prospective purchaser of a security, you should undertake such independent investigation of Nuveen as in your judgment is appropriate to make an informed decision with respect to an investment in Nuveen Stock.

Price Range of Nuveen Stock

Nuveen Stock is listed on the New York Stock Exchange under the symbol “JNC.” The following table sets forth the high and low prices as reported by the New York Stock Exchange.

S-8

Table of Contents

RISK FACTORS

The securities are not secured debt and are riskier than ordinary unsecured debt securities. Because the return to investors is based on the performance of Nuveen Stock, there is no guaranteed return of principal and you may lose up to your entire investment. This section describes the most significant risks relating to the securities. You should carefully consider, in addition to the other information set forth or incorporated by reference in this prospectus supplement and in the accompanying prospectus, the following information and the information that Nuveen publicly files with the SEC. Prospective holders are advised that none of the documents that Nuveen files with the SEC are incorporated by reference herein or in any way made a part of this prospectus supplement or the accompanying prospectus. You should also carefully consider whether the securities are suited to your particular circumstances before you decide to purchase them.

The securities are not ordinary senior debt securities; you will bear the full risk of a decline in the value of Nuveen Stock.

The securities combine features of equity and debt. The terms of the securities differ from those of ordinary debt securities in that we will not pay you a fixed amount at maturity. Our payout to you at maturity will be a number of shares of Nuveen Stock and/or, at our option, an amount of cash, based on the closing price of Nuveen Stock on each of the thirty valuation dates, which are scheduled to be the thirty consecutive trading days commencing August 29, 2007, unless the maturity of the securities has been accelerated. If the closing price of Nuveen Stock on one or more of the valuation dates is less than the initial price of the securities, we may pay you an amount of Nuveen Stock and/or cash with a value that is less than the principal amount of the securities and may be zero.

If the price of Nuveen Stock is lower on the maturity date than it was on the applicable valuation date, the value of any Nuveen Stock you receive on the maturity date will be less than it would have been had you received it on the applicable valuation date.

Your appreciation potential is less than with direct ownership of Nuveen Stock.

The market value of the Nuveen Stock (or the partial or total cash equivalent of such Nuveen Stock) that you will receive at maturity represented by the total exchange amount will exceed the issue price of the securities only if the closing price per share of Nuveen Stock on a sufficient number of valuation dates exceeds the threshold appreciation price of $40.80. The threshold appreciation price represents an appreciation of 20% over the initial price of $34.00. Therefore, an investment in the securities affords less opportunity for equity appreciation than with a direct investment in Nuveen Stock. If the closing price per share of Nuveen Stock on any valuation date exceeds the initial price of $34.00, but does not exceed the threshold appreciation price, you will realize no equity appreciation of the Nuveen Stock in the exchange amount for any such valuation date. Furthermore, if the closing price per share of Nuveen Stock on any valuation date exceeds the threshold appreciation price, you will realize only 83.33% of the increase in the value of the Nuveen Stock over the threshold appreciation price with respect to the exchange amount determined on such valuation date.

The securities will not be listed.

The securities will not be listed on any securities exchange. There may be little or no secondary market for the securities. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the securities easily. MLPF&S currently intends to act as a market maker for the securities but is not required to do so. Because we do not expect that other market makers will participate significantly in the secondary market for the securities, the price at which you may be able to trade your securities is likely to depend on the price, if any, at which MLPF&S is willing to transact. If at any time MLPF&S were to cease acting as a market maker, it is likely that there would be little or no secondary market for the securities.

S-9

Table of Contents

Market price of the securities will be influenced by many unpredictable factors.

Several factors, many of which are beyond our control, will influence the value of the securities in the secondary market and the price at which MLPF&S may be willing to purchase or sell the securities in the secondary market. We expect that generally the closing price of Nuveen Stock on any day will affect the value of the securities more than any other single factor. However, because an investor in the securities receives a payout based on the exchange amounts as calculated on each of the valuation dates, the securities may trade differently from Nuveen Stock. Other factors that may influence the value of the securities include:

Some or all of these factors will influence the price you will receive if you sell your securities prior to maturity. For example, you may have to sell your securities at a substantial discount from the principal amount if the closing price of Nuveen Stock is at, below, or not sufficiently above the issue price of the securities.

You cannot predict the future performance of Nuveen Stock based on its historical performance. The price of Nuveen Stock may decrease so that you will receive at maturity an amount of Nuveen Stock worth less than the principal amount of the securities. In addition, there can be no assurance that the price of Nuveen Stock will increase above the threshold appreciation price so that you will receive at maturity an amount of Nuveen Stock worth more than the principal amount of the securities. See “Where You Can Find More Information—Nuveen Investments, Inc.” for more information regarding Nuveen and Nuveen Stock.

The concurrent offerings will likely affect the value of the securities.

Concurrently with the initial offering of the securities, St. Paul Travelers offered to the public 39,309,155 shares of Nuveen Stock (43,240,071 shares if the underwriters exercise an over-allotment option in full), representing approximately 42% of the outstanding shares of Nuveen Stock (approximately 46% if the over-allotment option is exercised in full), which significantly increased the amount of Nuveen Stock available for public trading. In addition, we understand that Morgan Stanley issued and sold, in a registered offering, an aggregate of $275,060,000 of its 5.875% Mandatorily Exchangeable Securities due October 15, 2008 that will be mandatorily exchangeable for between 6,741,397 and 8,090,000 shares of Nuveen Stock based on the closing price of Nuveen Stock over a thirty trading day period prior to the maturity of such mandatorily exchangeable debt securities. These concurrent offerings will likely affect the price of Nuveen Stock and, accordingly, the value of the securities.

ML&Co. is not affiliated with St. Paul Travelers and St. Paul Travelers has no obligation with respect to the securities.

We have no affiliation with St. Paul Travelers, and St. Paul Travelers has no obligations with respect to the securities or amounts to be paid to holders of the securities, including any obligation to take our needs or the needs of holders of the securities into consideration for any purpose. St. Paul Travelers is not responsible for the determination or calculation of the amount receivable by holders of the securities at maturity. The forward sale

S-10

Table of Contents

agreement between a subsidiary of ours and St. Paul Travelers is a commercial transaction and does not create any rights in, or for the benefit of, any third party, including any holder of the securities. See the section of this prospectus supplement called “Use of Proceeds and Hedging.”

In the event St. Paul Travelers does not perform under the forward sale agreement, we will still be required to acquire shares of Nuveen Stock for delivery to the holders of the securities, unless we elect to exercise our option to deliver cash with an equal value.

ML&Co. is not affiliated with Nuveen and Nuveen has no obligations with respect to the securities.

Nuveen is not an affiliate of ours. Consequently, we have no ability to control the actions of Nuveen, including any corporate actions of the type that would require the calculation agent to adjust the payout to you at maturity. Nuveen has no obligation to consider your interest as an investor in the securities in taking any corporate actions that might affect the value of your securities. In addition, Nuveen has no obligations with respect to the securities or amounts to be paid to holders of the securities. None of the money you pay for the securities will go to Nuveen.

ML&Co. may engage in business with or involving Nuveen without regard to your interests.

We or our affiliates may presently or from time to time engage in business with Nuveen without regard to your interests, including extending loans to, or making equity investments in, Nuveen or providing advisory services to Nuveen, including merger and acquisition advisory services. In the course of our business, we or our affiliates may acquire non-public information about Nuveen. Neither we nor any of our affiliates undertakes to disclose any such information to you. In addition, we or our affiliates from time to time have published and in the future may publish research reports with respect to Nuveen. These research reports may or may not recommend that investors buy or hold Nuveen Stock.

You have no shareholder rights.

Investing in the securities is not equivalent to investing in Nuveen Stock. As an investor in the securities, you will not have voting rights or rights to receive dividends or other distributions or any other rights with respect to Nuveen Stock. In addition, you do not have the right to exchange your securities for Nuveen Stock, unless we elect to deliver Nuveen Stock in connection with the maturity of the securities.

The adjustments to the exchange ratio that the calculation agent is required to make do not cover every corporate event that can affect the value of Nuveen Stock and in some circumstances may result in a reduction to the exchange ratio.

MLPF&S, as calculation agent, will adjust the amount payable at maturity for certain events affecting the value of Nuveen Stock, such as stock splits and stock dividends, increases or decreases in the regular quarterly dividend, other dividends or distributions and certain other corporate actions involving Nuveen, such as mergers. However, the calculation agent will not make an adjustment for every corporate event that can affect the value of Nuveen Stock. For example, the calculation agent is not required to make any adjustments if Nuveen or anyone else makes a partial tender or partial exchange offer for Nuveen Stock or for offerings by Nuveen of Nuveen Stock for cash or in connection with acquisitions or for sales of Nuveen Stock by St. Paul Travelers. If an event occurs that does not require the calculation agent to adjust the amount of Nuveen Stock payable at maturity, the closing price of the securities may be materially and adversely affected.

In addition, if the regular quarterly dividend on Nuveen Stock declines below $0.18 per share, the calculation agent will adjust the exchange ratio downward, as described under “Description of Securities—Antidilution Adjustments.”

S-11

Table of Contents

The economic interests of the calculation agent and other affiliates of ours are potentially adverse to your interests.

The economic interests of the calculation agent and other affiliates of ours are potentially adverse to your interests as an investor in the securities.

As calculation agent, MLPF&S will calculate the payout to you at maturity of the securities and will determine what adjustments should be made to the exchange ratio to reflect certain corporate and other events. Determinations made by MLPF&S, in its capacity as calculation agent, including adjustments to the exchange ratio, may affect the amount payable to you at maturity. See the sections of this prospectus supplement called “Description of Securities—Exchange at Maturity” and “—Antidilution Adjustments.”

Hedging and trading activity by the calculation agent and its affiliates could potentially affect the value of the securities.

MLPF&S and other subsidiaries of ours have carried out and will continue to carry out hedging activities related to the securities including trading in Nuveen Stock as well as in other instruments related to Nuveen Stock. MLPF&S and some of our other subsidiaries also trade Nuveen Stock and other financial instruments related to Nuveen Stock on a regular basis as part of their general broker-dealer and other businesses. Any of these hedging or trading activities during the term of the securities could potentially affect the price of Nuveen Stock on the valuation dates and, accordingly, the value of the exchange amounts you will receive at maturity.

Because the characterization of the securities for U.S. federal income tax purposes is uncertain, the material U.S. federal income tax consequences of an investment in the securities are uncertain.

You should also consider the U.S. federal income tax consequences of investing in the securities. There are no statutory provisions, regulations, published rulings or judicial decisions addressing or involving the characterization and treatment, for U.S. federal income tax purposes, of the securities or of securities with terms substantially the same as the securities. Accordingly, the United States federal income tax consequences of an investment in the securities are complex and uncertain. Pursuant to the terms of the securities, ML&Co. and you agree, in the absence of an administrative or judicial ruling to the contrary, to characterize each security for all tax purposes as an investment unit consisting of a debt instrument of ML&Co. and a forward contract to acquire a variable number of shares of Nuveen Stock (subject to ML&Co.’s right to elect cash settlement). Under this characterization of the securities, for United States federal income tax purposes, you will generally include payments of interest made on the securities in income in accordance with your regular method of tax accounting. If the IRS were successful in asserting an alternative characterization of the securities, the timing and character of income, gain or loss recognized with respect to the securities and your basis in any shares of Nuveen Stock received by you might significantly differ from that which is described in this prospectus supplement. We do not plan to request a ruling from the IRS regarding the tax treatment of the securities, and the IRS or a court may not agree with the tax treatment described in this prospectus supplement. You should review the discussion under the section entitled “United States Federal Income Taxation” in this prospectus supplement.

You are urged to consult your own tax advisor regarding all aspects of the U.S. federal income tax consequences of investing in the securities, as well as any tax consequences arising under the laws of any state, local or foreign taxing jurisdiction.

S-12

Table of Contents

USE OF PROCEEDS AND HEDGING

This prospectus supplement and the accompanying prospectus are to be delivered in connection with sales of securities by MLPF&S and its affiliates in market making transactions. We will not receive any of the proceeds from such transactions. In connection with the original issuance of the securities, we used the proceeds, in part, in connection with hedging our obligations under the securities through one or more of our subsidiaries and for general corporate purposes. See also “Use of Proceeds” in our accompanying prospectus.

On the date the securities were priced in connection with their issuance, we, through our subsidiaries, hedged, in part, our anticipated exposure in connection with the securities by entering into a forward sale agreement with St. Paul Travelers pursuant to which St. Paul Travelers has agreed to deliver, subject to St. Paul Travelers’ right to cash settle such forward sale agreement, an aggregate of 5,824,800 shares of Nuveen Stock. On the closing date of the initial offering of the securities, a subsidiary of ours paid St. Paul Travelers a price, calculated at a discount from the public offering price of Nuveen Stock in the concurrent secondary offering, for the shares of Nuveen Stock underlying the forward contract.

We have no affiliation with St. Paul Travelers, and St. Paul Travelers has no obligations with respect to the securities or amounts to be paid to holders of the securities, including any obligation to take our needs or the needs of holders of the securities into consideration for any purpose. In the event St. Paul Travelers does not perform under the forward sale agreement, we will be required to otherwise acquire shares of Nuveen Stock for delivery to the holders of the securities, unless and to the extent we elect to exercise our option to deliver cash in respect of some or all of the total exchange amount.

In addition, through our subsidiaries, we are likely to modify our hedge position throughout the life of the securities by purchasing, selling and short selling in the public market Nuveen Stock, options contracts on Nuveen Stock listed on major securities markets or positions in any other available securities or instruments that we may wish to use in connection with such hedging activities. Our subsidiaries may borrow shares of Nuveen Stock from stock lenders in connection with such short sales. We cannot give any assurance that our hedging activities will not affect the price of Nuveen Stock and, therefore, adversely affect the value of the securities or the payment you will receive at maturity or upon any acceleration of the securities.

S-13

Table of Contents

DESCRIPTION OF SECURITIES

The following description of the particular terms of the 6.75% Mandatorily Exchangeable Securities due October 15, 2007, which we refer to as the securities, offered hereby supplements and, to the extent inconsistent with, replaces the descriptions of the general terms and provisions of the debt securities set forth in our prospectus, to which description reference is hereby made. The securities are a series of our debt securities described in our accompanying prospectus and are referred to therein as “STRYPES.” The following summary of the securities is qualified in its entirety by reference to the indenture referred to in our prospectus.

General

The securities will initially be limited to $275,060,000 in aggregate principal amount and will mature on October 15, 2007, subject to acceleration as described below under “—Antidilution Adjustments” and “—Acceleration Upon an Event of Default,” and subject to extension in the event of a market disruption event (as defined below) or the unscheduled occurrence of a non-trading day on or after August 29, 2007 as described below under “—Exchange at Maturity.” The securities were initially sold at $34.00 per security, which we refer to as the “issue price.” If, due to a market disruption event or otherwise, any valuation date occurs after October 10, 2007, the maturity date will be the third business day following the final valuation date as postponed; provided that the maturity date shall be no later than November 15, 2007. We may not redeem the securities prior to the maturity date, and you will not have the option to cause us to repurchase the securities or to exchange the securities for Nuveen Stock and/or cash prior to the maturity date.

The securities, the terms of which have been established pursuant to an officer’s certificate under the indenture referred to in our accompanying prospectus, will constitute senior unsecured debt and will rank on parity with all other senior unsecured indebtedness of ML&Co. and with all other unsecured and unsubordinated indebtedness of ML&Co., subject to certain statutory exceptions in the event of liquidation upon insolvency. The securities have been issued in fully registered form only, in denominations of $34.00 and integral multiples thereof. Principal of and interest on the securities will be payable, and the transfer of securities will be registrable, through the depositary as described below.

As used herein “business day” means any day, other than a Saturday or Sunday, that is neither a legal holiday nor a day on which banking institutions are authorized or required by law or regulation to close in The City of New York. “Trading day” means a day, as determined by the calculation agent, on which trading is generally conducted on the New York Stock Exchange, Inc. (“NYSE”), the American Stock Exchange LLC, the Nasdaq National Market, the Chicago Mercantile Exchange and the Chicago Board of Options Exchange and in the over-the-counter market for equity securities in the United States.

The trustee for the securities is JPMorgan Chase Bank, N.A. (formerly known as JPMorgan Chase Bank), which we refer to as the Trustee.

References to payment “per security” refer to each $34.00 principal amount of securities.

Interest on the Securities

The securities will bear interest from April 12, 2005, the issue date, to but excluding the scheduled maturity date at a rate of 6.75% per annum (equivalent to $2.295 per annum per security). We will pay interest on the securities each January 15, April 15, July 15 and October 15, commencing July 15, 2005 to and including the maturity date, which we refer to as the “interest payment dates.” If the scheduled maturity date is postponed because a valuation date occurs after October 10, 2007 or otherwise, we will pay interest on the maturity date as postponed rather than on the scheduled maturity date, but no interest will accrue on the securities or on such payment during the period from or after the scheduled maturity date. If any scheduled interest payment date (other than the maturity date) is not a business day, we will pay interest on the next business day, but interest on that payment will not accrue during the period from and after the scheduled interest payment date. The “record

S-14

Table of Contents

date” for each interest payment date, other than the interest payment date that coincides with the maturity date, will be the date 15 calendar days prior to such scheduled interest payment date, whether or not that date is a business day. Interest payable on the maturity date will be payable to holders presenting the securities for mandatory exchange at maturity.

Interest will be computed on the basis of a 360-day year of twelve 30-day months and will accrue from and including the most recent interest payment date to which interest has been paid or duly provided for, or, if no interest has been paid or duly provided for, from and including the issue date. Interest will accrue to but excluding the next interest payment date, or, if earlier, the date on which the principal has been paid or duly made available for payment, except as described below. Interest payments will include accrued interest from and including the date of issue or from and including the last date in respect of which interest has been paid, as the case may be, to but excluding the relevant interest payment date or scheduled maturity date.

Exchange at Maturity

At maturity, we will, or will cause the trustee to, deliver an aggregate amount of Nuveen Stock and/or cash per security equal to the sum of the exchange amounts as determined on each of the thirty valuation dates, which we refer to as the “total exchange amount.” The exchange amount for each valuation date is determined as described below. Unless the maturity of the securities has been accelerated, upon delivery of the securities to the trustee, we will apply the $34.00 principal amount of each security as payment for and will, or will cause the trustee to, deliver the total exchange amount on the maturity date, together with accrued and unpaid interest.

The “valuation dates” will be the first thirty trading days on which no market disruption event shall have occurred beginning August 29, 2007; provided that the last valuation date shall be no later than November 12, 2007.

If, due to a market disruption event or otherwise, the final valuation date has not occurred by November 12, 2007, all remaining valuation dates will be deemed to occur on November 12, 2007, and the closing price for each of the remaining valuation dates will be the closing price on November 12, 2007, or if there is a market disruption event on that day the market value per share of Nuveen Stock as determined by the calculation agent.

Exchange Amount

The exchange amount per security as determined on each valuation date will be determined by the calculation agent as follows:

The amount of cash to be delivered in lieu of shares of Nuveen Stock for any applicable valuation date will equal the number of such shares multiplied by the closing price of Nuveen Stock on such valuation date.

The exchange ratio is initially set at 1.0 and is subject to adjustment upon the occurrence of certain corporate events relating to Nuveen. See “—Antidilution Adjustments” below.

S-15

Table of Contents

The “initial price” is the original issue price, or $34.00. The “exchange price” on any valuation date means the product of (i) the closing price of one share of Nuveen Stock and (ii) the exchange ratio, each as determined on such valuation date.

The “closing price” for one share of Nuveen Stock (or one unit of any other security for which a closing price must be determined) on any trading day (as defined below) means:

If Nuveen Stock (or any such other security) is listed or admitted to trading on any national securities exchange or is a security traded on the Nasdaq National Market but the last reported sale price or Nasdaq official closing price, as applicable, is not available pursuant to the preceding sentence, then the closing price for one share of Nuveen Stock (or one unit of any such other security) on any trading day will mean the last reported sale price of the principal trading session on the over-the-counter market as reported on the Nasdaq National Market or the OTC Bulletin Board on such day. If, because of a market disruption event or otherwise, the last reported sale price or Nasdaq official closing price, as applicable, for Nuveen Stock (or any such other security) is not available pursuant to either of the two preceding sentences, then the closing price for any trading day will be the mean, as determined by the calculation agent, of the bid prices for Nuveen Stock (or any such other security) obtained from as many recognized dealers in such security, but not exceeding three, as will make such bid prices available to the calculation agent. Bids of MLPF&S or any of its affiliates may be included in the calculation of such mean, but only to the extent that any such bid is the highest of the bids obtained. The term “security traded on the Nasdaq National Market” will include a security included in any successor to such system, and the term “OTC Bulletin Board Service” will include any successor service thereto.

If the security is an American Depositary Receipt (an “ADR”), the closing price for such security means (i) the closing price for such ADR determined as set forth above, or (ii) if the ADRs are not traded, the product of (a) the closing price per share (or, if no closing price per share is reported, the last reported per share sale price) of the shares represented by such ADR on the principal securities exchange on which such shares are listed on such date, or, if such shares are not listed for trading on a securities exchange on such date, the per share market value of such shares on such date as determined by a nationally recognized independent investment banking firm retained for this purpose by the calculation agent; (b) the number of shares represented by such ADR; and (c) the U.S. dollar noon buying rate in New York City for cable transfers of the relevant currency for U.S. dollars as certified by the Federal Reserve Bank of New York on such date.

Settlement

We shall, or shall cause the calculation agent to, (i) provide written notice to the Trustee and to the depositary, on or prior to the fifth business day immediately prior to the first valuation date, of our elections with respect to each of the thirty valuation dates as to whether we will deliver shares of Nuveen Stock or cash to the

S-16

Table of Contents

Trustee for the benefit of holders of the securities in respect of each such valuation date, which election we can change by providing written notice to the Trustee and the depositary at least three business days prior to the valuation date for which such change is to take effect, (ii) provide written notice to the Trustee and to the depositary, on the business day following each valuation date, of the exchange amount for such valuation date, and (iii) deliver such shares of Nuveen Stock (and cash in respect of interest and any fractional shares of Nuveen Stock) or cash, as the case may be, in respect of each such valuation date to the Trustee on or before the maturity date. We expect such shares and/or cash will be distributed to investors on the maturity date in accordance with the standard rules and procedures of DTC and its direct and indirect participants. See “—Book-Entry, Delivery and Form” below.

We will have the option to deliver the Nuveen Stock or cash constituting the exchange amount with respect to one or more valuation dates to the Trustee for the benefit of the holders of the securities prior to the maturity date. Our delivery of such Nuveen Stock and/or cash to the Trustee will be irrevocable and will satisfy our obligation to deliver those shares of Nuveen Stock and/or cash on the maturity date. We refer to any day on which we make such a delivery of Nuveen Stock and/or cash as a “settlement date.” After the delivery of the exchange amount on any settlement date, we will have no ownership interest in the Nuveen Stock or cash we have delivered. The Trustee will hold such Nuveen Stock and/or cash for the benefit of the holders of the securities and will distribute them to the holders of the securities on the maturity date, unless required by law or regulation to deliver such shares or cash prior to the maturity date.

In addition, we may elect to make an irrevocable delivery of Nuveen Stock to the Trustee prior to any valuation date, in an amount no greater than .8333 shares per security, for the benefit of the holders of the securities. To the extent of any such delivery, our obligation to deliver Nuveen Stock with respect to one or more valuation dates will be reduced accordingly.

If, while the Trustee is holding Nuveen Stock for the benefit of the holders of the securities, the Trustee receives any solicitation for any vote or other action to be taken with respect to Nuveen Stock, the Trustee shall abstain from voting or taking such action.

If we elect to deliver shares of Nuveen Stock with respect to the exchange amount determined on any valuation date but we have not yet delivered such shares to the Trustee, the calculation agent will adjust the amount of Nuveen Stock to be delivered during the period following the relevant valuation date to but excluding the settlement date on which such exchange amount is delivered to the Trustee on account of the occurrence of any of the events set forth under “—Antidilution Adjustments” below that would require an adjustment to the exchange ratio.

If the maturity of the securities is accelerated because of an event of default acceleration (as defined under “—Acceleration Upon an Event of Default” below), we shall provide such notice as promptly as possible and in no event later than two business days after the date of acceleration.

No Fractional Shares

On the maturity date, we will deliver the aggregate number of shares of Nuveen Stock and/or cash due with respect to all of such securities, as described above, but, if we deliver shares, we will pay cash in lieu of delivering any fractional share of Nuveen Stock in an amount equal to the corresponding fractional closing price of such fraction of a share of Nuveen Stock as determined by the calculation agent as of the final valuation date.

Calculation Agent

The calculation agent for the securities is MLPF&S, which we refer to as the “calculation agent.” All determinations made by the calculation agent, will be at the sole discretion of the calculation agent and will, in the absence of manifest error, be conclusive for all purposes and binding on you, the Trustee and us.

S-17

Table of Contents

All calculations with respect to the exchange ratio for the securities will be made by the calculation agent and will be rounded to the nearest one hundred-thousandth, with five one-millionths rounded upward (e.g., .876545 would be rounded to .87655), and all dollar amounts paid to you in the aggregate related to interest payments or payouts at maturity resulting from such calculations will be rounded to the nearest cent with one-half cent rounded upward.

Because the calculation agent is our affiliate, the economic interests of the calculation agent and its affiliates may be adverse to your interests as an investor in the securities, including with respect to certain determinations and judgments that the calculation agent must make in making adjustments to the exchange ratio or other antidilution adjustments or determining any closing price or whether a market disruption event has occurred or calculating the amount payable to you in the event of any acceleration. See “—Antidilution Adjustments,” “—Market Disruption Event” and “—Acceleration Upon an Event of Default” below. MLPF&S is obligated to carry out its duties and functions as calculation agent in good faith and using its reasonable judgment.

Antidilution Adjustments

The exchange ratio will be adjusted by the calculation agent upon the occurrence of the events described below, as follows:

1. Stock splits.    If Nuveen Stock is subject to a stock split or reverse stock split, then once such split has become effective, the exchange ratio will be adjusted to equal the product of the prior exchange ratio and the number of shares issued in such stock split or reverse stock split with respect to one share of Nuveen Stock.

2. Stock dividends.    If Nuveen Stock is subject

(i) to a stock dividend (issuance of additional shares of Nuveen Stock) that is given ratably to all holders of shares of Nuveen Stock, or

(ii) to a distribution of Nuveen Stock as a result of the triggering of any provision of the corporate charter of Nuveen,

then at the close of business on the record date for such dividend, the exchange ratio will be adjusted so that the new exchange ratio shall equal the prior exchange ratio plus the product of (i) the number of shares to be issued with respect to one share of Nuveen Stock and (ii) the prior exchange ratio.

3. Rights or Warrants.    If Nuveen issues rights or warrants to all holders of Nuveen Stock to subscribe for or purchase Nuveen Stock at an exercise price per share less than the closing price of Nuveen Stock on both

(i) the date the exercise price of such rights or warrants is determined, and

(ii) the expiration date of such rights or warrants,

and if the expiration date of such rights or warrants precedes the maturity of the securities,

then the exchange ratio will be adjusted to equal the product of the prior exchange ratio and a fraction:

The numerator of this fraction will be:

the number of shares of Nuveen Stock outstanding immediately prior to the issuance of such rights or warrants plus the number of additional shares of Nuveen Stock offered for subscription or purchase pursuant to such rights or warrants.

The denominator of this fraction will be:

the number of shares of Nuveen Stock outstanding immediately prior to the issuance of such rights or warrants plus a number of additional shares of Nuveen Stock equal to:

(i) the total number of shares offered for subscription or purchase pursuant to such right or warrants multiplied by the exercise price of such rights or warrants,

S-18

Table of Contents

divided by

(ii) the closing price of Nuveen Stock on the expiration date of such rights or warrants.

4. Ordinary Dividends.    In the event of any increase or decrease on or after April 6, 2005 in the regular quarterly cash dividend payable to holders of Nuveen Stock relative to the Base Quarterly Dividend (as defined below), the exchange ratio will be adjusted as of the related ex-dividend date for such quarterly cash dividend.

The new exchange ratio will equal the prior exchange ratio times a fraction:

The numerator of this fraction will be:

The Base Closing Price minus the Base Quarterly Dividend.

The denominator of this fraction will be:

The Base Closing Price minus the amount per share of such dividend or distribution.

For purposes of this calculation the “Base Quarterly Dividend” means a quarterly dividend of $.18 per share. The amount of the Base Quarterly Dividend is subject to adjustment by the calculation agent in its sole discretion in a manner inversely proportional to any adjustment to the exchange ratio in the case of any stock split or reverse stock split described in paragraph 1 or any stock dividend or distribution described in paragraph 2.

For purposes of this calculation, the “Base Closing Price” means the closing price of Nuveen Stock on the trading day preceding the ex-dividend date for the payment of such cash dividend.

The “ex-dividend date” means the day on and after which transactions in Nuveen Stock on an organized securities exchange or trading system no longer carry the right to receive the cash dividend or other cash distribution.

5. Other Cash or Non-Cash Dividends.

(a) If a cash dividend or distribution (excluding any dividends or distributions described in paragraph 4, including a regular quarterly dividend equal to the Base Quarterly Dividend, or paragraph 6) occurs with respect to Nuveen Stock, the exchange ratio with respect to Nuveen Stock will be adjusted on the ex-dividend date with respect to such cash dividend or distribution.

The new exchange ratio will equal the product of the then current exchange ratio and a fraction:

The numerator of this fraction will be the Base Closing Price.

The denominator of this fraction will be the Base Closing Price minus the cash dividend or distribution.

For purposes of this calculation, the “Base Closing Price” means the closing price of Nuveen Stock on the trading day preceding the ex-dividend date for the payment of such cash dividend or distribution.

(b) If a non-cash dividend or distribution (excluding any non-cash dividends or distributions described in paragraph 2, paragraph 3 or paragraph 6) occurs with respect to Nuveen Stock, the exchange ratio with respect to Nuveen Stock will be adjusted on the ex-dividend date with respect to such non-cash dividend or distribution.

The new exchange ratio will equal the product of the then current exchange ratio and a fraction:

The numerator of this fraction will be the Base Closing Price.

The denominator of this fraction will be the Base Closing Price minus the full cash value of the non-cash dividend or distribution.

S-19

Table of Contents

For purposes of this calculation, the “Base Closing Price” means the closing price of Nuveen Stock on the trading day preceding the ex-dividend date for the payment of such non-cash dividend or distribution.

To the extent a dividend or distribution is not paid in cash, the value of the non-cash component will be determined by the calculation agent, whose determination shall be conclusive. A distribution on Nuveen Stock described in clause (i), (iv) or (v) of the first sentence of paragraph 6 below shall cause an adjustment to the exchange ratio pursuant only to clause (i), (iv) or (v) of the first sentence of paragraph 6, as applicable.

6. Reorganization Events.    Any of the following shall constitute a “Reorganization Event”:

(i) Nuveen’s stock is reclassified or changed, including, without limitation, as a result of the issuance of any tracking stock by Nuveen,

(ii) Nuveen or any surviving entity or subsequent surviving entity of Nuveen (a “Nuveen Successor”) has been subject to a merger, combination or consolidation and is not the surviving entity,

(iii) Nuveen or any Nuveen Successor completes a statutory exchange of securities with another corporation (other than pursuant to clause (ii) above),

(iv) Nuveen or any Nuveen Successor is liquidated,

(v) Nuveen or any Nuveen Successor issues to all of its shareholders equity securities of an issuer other than Nuveen (other than in a transaction described in clause (ii), (iii) or (iv) above) (a “Spin-off Event”), or

(vi) all of the outstanding shares of Nuveen Stock are acquired pursuant to a tender offer, exchange offer or going private transaction.

If any Reorganization Event occurs, in each case as a result of which the holders of Nuveen Stock receive any equity security listed on a national securities exchange or traded on The Nasdaq National Market (a “Marketable Security”), other securities or other property, assets or cash, including (i) in the case of the issuance of tracking stock, the reclassified share of Nuveen Stock, (ii) in the case of a Spin-off Event, the share of Nuveen Stock with respect to which the spun-off security was issued, and (iii) in the case of any other Reorganization Event where Nuveen Stock continues to be held by the holders receiving such distribution, the Nuveen Stock (collectively “Exchange Property”), the amount payable per each security with respect to any valuation date following the effective date for such Reorganization Event (or, if applicable, in the case of spinoff stock, the ex-dividend date for the distribution of such spinoff stock) will be adjusted to provide that each holder of a security may receive Exchange Property or, at our option, the cash value of such Exchange Property on the maturity date.

Following the effective date for such Reorganization Event (or, if applicable, in the case of spinoff stock, the ex-dividend date for the distribution of such spinoff stock), the method of determining the exchange price used to calculate the exchange amount on any valuation date will be adjusted so that the exchange price will mean the Transaction Value as of the valuation date.

“Transaction Value” at any valuation date means the sum of:

(i) for any cash received in any such Reorganization Event, the amount of cash received per share of Nuveen Stock as adjusted by the exchange ratio at the time of such Reorganization Event,

(ii) for any property other than cash or Marketable Securities received in any such Reorganization Event, the market value, as determined by the calculation agent, as of the date of receipt, of such Exchange Property received for each share of Nuveen Stock, as adjusted by the exchange ratio at the time of such Reorganization Event, and

S-20

Table of Contents

(iii) for any Marketable Securities received in any such Reorganization Event, an amount equal to the closing price per share, as of such valuation date, of such security multiplied by the quantity of such security received for each share of Nuveen Stock, as adjusted by the exchange ratio at the time of such Reorganization Event (and as the exchange ratio for such Marketable Security may have been subsequently adjusted to and including the applicable valuation date).

Reorganization Event Acceleration if Solely Cash Consideration.    Notwithstanding the above, if the Exchange Property received in any such Reorganization Event consists only of cash, the maturity date of the securities will be deemed to be accelerated (a “Reorganization Event Acceleration”) to the third business day immediately following the date on which such cash is distributed to holders of Nuveen Stock (the “date of acceleration”).

On such date of acceleration holders will receive for each security in lieu of any Nuveen Stock and as liquidated damages in full satisfaction of ML&Co.’s obligations under the securities an amount of cash equal to:

(a) if the Transaction Value is equal to or less than the initial price, the Transaction Value,

(b) if the Transaction Value is less than or equal to the threshold appreciation price but is greater than the initial price, the initial price, and

(c) if the Transaction Value is greater than the threshold appreciation price, the product of the threshold participation factor and the Transaction Value,

plus, in each case, accrued but unpaid interest to but excluding the date of acceleration.

If Exchange Property consists of more than one type of property and we do not elect to deliver cash with respect to any valuation date, we will deliver to the trustee for the benefit of the holders of the securities, a pro rata share of each such type of Exchange Property. We expect that such Exchange Property will be distributed to investors in accordance with the standard rules and procedures of DTC and its direct and indirect participants. If Exchange Property includes a cash component, investors will not receive any interest accrued on such cash component. In the event Exchange Property consists of Marketable Securities, those Marketable Securities will, in turn, be subject to the antidilution adjustments set forth in paragraphs 1 through 6, except that the calculation agent may make any modifications to such adjustments as it may reasonably determine.

For purposes of paragraph 6 above, in the case of a consummated tender or exchange offer or going-private transaction involving consideration of particular types, Exchange Property shall be deemed to include the amount of cash or other property delivered by the offeror in the tender or exchange offer (in an amount determined on the basis of the rate of exchange in such tender or exchange offer or going-private transaction). In the event of a tender or exchange offer or a going-private transaction in which an offeree may elect to receive cash or other property, Exchange Property shall be deemed to include the kind and amount of cash and other property received by offerees who elect to receive cash.

Following the occurrence of any Reorganization Event referred to in paragraph 6 above, (i) references to “Nuveen Stock” under “—No Fractional Shares,” “—Exchange at Maturity” and “—Market Disruption Event” shall be deemed to also refer to any other security received by holders of Nuveen Stock in any such Reorganization Event, and (ii) all other references in this prospectus supplement to “Nuveen Stock” shall be deemed to refer to the Exchange Property into which the securities are thereafter exchangeable and references to a “share” or “shares” of Nuveen Stock shall be deemed to refer to the applicable unit or units of such Exchange Property, unless the context otherwise requires.

If the closing price is no longer available for Nuveen Stock for whatever reason, including the liquidation of Nuveen or the subjection of Nuveen to a proceeding under any applicable bankruptcy, insolvency or other similar law, then the value of Nuveen Stock will equal zero for so long as no closing price is available.

S-21

Table of Contents

The exchange ratio resulting from any of the adjustments specified above will be rounded to the nearest one hundred-thousandth, with five one-millionths rounded upward. Adjustments to the exchange ratios with respect to any Nuveen Stock or Exchange Property will be made up to the close of business on the final valuation date.

No adjustments to the exchange ratio or method of calculating the exchange ratio will be required other than those specified above. The adjustments specified above do not cover all events that could affect the closing price of Nuveen Stock, including, without limitation, a partial tender or exchange offer for Nuveen Stock, offerings of Nuveen Stock by Nuveen for cash or in connection with acquisitions or sales of Nuveen Stock by St. Paul Travelers.

The calculation agent shall be solely responsible for the determination and calculation of any adjustments to the exchange ratio or of any related determinations and calculations with respect to any distributions of stock, other securities or other property or assets (including cash) in connection with any corporate event described in paragraphs 1 through 6 above, and its determinations and calculations with respect thereto shall be conclusive in the absence of manifest error.

The calculation agent will, upon the occurrence of an event that requires an adjustment to the exchange ratio or the occurrence of a Reorganization Event (or, in either case, if the calculation agent is not aware of such occurrence, as soon as practicable after becoming so aware), promptly notify us, the trustee and DTC as holder of the securities in writing of the occurrence of such event including a statement setting forth the factors by which the exchange ratio is to be adjusted.

Market Disruption Event

A “market disruption event” means, with respect to Nuveen Stock:

(i) a suspension, absence or material limitation of trading of Nuveen Stock on the primary market for Nuveen Stock for more than two hours of trading or during the one-half hour period preceding the close of the principal trading session in such market; or a breakdown or failure in the price and trade reporting systems of the primary market for Nuveen Stock as a result of which the reported trading prices for Nuveen Stock during the last one-half hour preceding the close of the principal trading session in such market are materially inaccurate; or the suspension, absence or material limitation of trading on the primary market for trading in options contracts related to Nuveen Stock, if available, during the one-half hour period preceding the close of the principal trading session in the applicable market, in each case as determined by the calculation agent in its sole discretion; and

(ii) a determination by the calculation agent in its sole discretion that any event described in clause (i) above materially interfered with our ability or the ability of any of our subsidiaries to unwind or adjust all or a material portion of the hedge with respect to the securities.

For purposes of determining whether a market disruption event has occurred: (1) a limitation on the hours or number of days of trading will not constitute a market disruption event if it results from an announced change in the regular business hours of the relevant exchange, (2) a decision to permanently discontinue trading in the relevant options contract will not constitute a market disruption event, (3) limitations pursuant to NYSE Rule 80A (or any applicable rule or regulation enacted or promulgated by the NYSE, any other self-regulatory organization or the Securities and Exchange Commission (the “Commission”) of scope similar to NYSE Rule 80A as determined by the calculation agent) on trading during significant market fluctuations shall constitute a suspension, absence or material limitation of trading, (4) a suspension of trading in options contracts on Nuveen Stock by the primary securities market trading such options, if available, by reason of (x) a price change exceeding limits set by such securities exchange or market, (y) an imbalance of orders relating to such contracts or (z) a disparity in bid and ask quotes relating to such contracts will constitute a suspension, absence or material limitation of trading in options contracts related to Nuveen Stock and (5) a suspension, absence or material

S-22

Table of Contents

limitation of trading on the primary securities market on which options contracts related to Nuveen Stock are traded will not include any time when such securities market is itself closed for trading under ordinary circumstances.

Acceleration Upon an Event of Default

In case an event of default by ML&Co. with respect to the securities shall have occurred and be continuing, the amount declared due and payable per security upon any acceleration of the securities (an “Event of Default Acceleration”) shall be determined by the calculation agent and shall be an amount equal to the sum of the exchange amounts (in each case using the cash value of such exchange amount) for each of thirty valuation dates, plus accrued but unpaid interest to but excluding the date of acceleration. For purposes of determining the exchange amounts, the acceleration date will be the first valuation date and the subsequent valuation dates will be the first twenty-nine trading days on which no market disruption event shall have occurred immediately following such date of acceleration.

Book-Entry, Delivery and Form

The securities have been issued in the form of one or more fully registered global securities which have been deposited with, or on behalf of, The Depository Trust Company, New York, New York, the “depositary” or “DTC,” and registered in the name of Cede & Co., the depositary’s nominee.

The depositary has advised ML&Co. as follows: the depositary is a limited-purpose trust company organized under the New York Banking Law, a “banking organization” within the meaning of the New York Banking Law, a member of the Federal Reserve System, a “clearing corporation” within the meaning of the New York Uniform Commercial Code, and a “clearing agency” registered pursuant to the provisions of Section 17A of the Securities Exchange Act of 1934, as amended. The depositary holds securities deposited with it by its participants and facilitates the settlement of transactions among its participants in those securities through electronic computerized book-entry changes in participant’s accounts, eliminating the need for physical movement of securities certificates. The depositary’s participants include securities brokers and dealers (including underwriters), banks, trust companies, clearing corporations and certain other organizations, some of whom (and/or their representatives) own the depositary. Access to the depositary’s book-entry system is also available to others, such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a participant, either directly or indirectly.

Purchases of the securities under the depositary’s system must be made by or through its direct participants, which will receive a credit for the securities on the depositary’s records. The ownership interest of each actual purchaser of each security (the beneficial owner) is in turn to be recorded on the records of direct and indirect participants. Beneficial owners will not receive written confirmation from the depositary of their purchase, but beneficial owners are expected to receive written confirmations providing details of the transaction, as well as periodic statements of their holdings, from the direct or indirect participants through which the beneficial owner entered into the transaction. Transfers of ownership interests in the securities are to be made by entries on the books of direct and indirect participants acting on behalf of beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the securities, except in the event that use of the book-entry system for the securities is discontinued.

To facilitate subsequent transfers, all securities deposited with the depositary are registered in the name of the depositary’s partnership nominee, Cede & Co, or such other name as may be requested by the depositary. The deposit of securities with the depositary and their registration in the name of Cede & Co. or such other nominee of the depositary do not effect any change in beneficial ownership. The depositary has no knowledge of the actual beneficial owners of the securities; the depositary’s records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may not be the beneficial owners. The participants will remain responsible for keeping account of their holdings on behalf of their customers.

S-23

Table of Contents

Conveyance of notices and other communications by the depositary to direct participants, by direct participants to indirect participants, and by direct participants and indirect participants to beneficial owners will be governed by arrangements among them, subject to any statutory or regulatory requirements as may be in effect from time to time.

Neither the depositary nor Cede & Co. (nor such other nominee of the depositary) will consent or vote with respect to the securities unless authorized by a direct participant in accordance with the depositary’s procedures. Under its usual procedures, the depositary mails an omnibus proxy to us as soon as possible after the applicable record date. The omnibus proxy assigns Cede & Co.’s consenting or voting rights to those direct participants identified in a listing attached to the omnibus proxy to whose accounts the securities are credited on the record date.

Payments in respect of the principal of and interest on the securities will be made to Cede & Co or such other nominee as may be requested by the depositary. The depositary’s practice is to credit direct participants accounts upon the depositary’s receipt of funds and corresponding detail information from us or any agent of ours, on the date payable in accordance with their respective holdings shown on the depositary’s records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the accounts of customers in bearer form or registered in street name, and will be the responsibility of such participant and not of the depositary or its nominee, the trustee, any agent of ours, or us, subject to any statutory or regulatory requirements as may be in effect from time to time. Payments of principal of and interest on the securities to Cede & Co. or such other nominee as may be requested by the depositary is the responsibility of us or of any paying agent of ours, disbursement of such payments to direct participants will be the responsibility of the depositary, and disbursement of such payments to the beneficial owners will be the responsibility of direct and indirect participants.

The depositary may discontinue providing its services as depositary with respect to the securities at any time by giving reasonable notice to us or our agent. Under such circumstances, in the event that a successor depositary is not obtained by us within 60 days, security certificates are required to be printed and delivered. In addition, we may be required to discontinue the use of the depositary’s book-entry system if an event of default by us occurs under the securities.

We may decide to discontinue use of the system of book-entry transfers through the depositary or any successor depositary. We understand, however, that under its current practices, the depositary would notify its participants of our request, but will only withdraw beneficial interests from a global security at the request of each participant. We would issue definitive certificates in exchange for any such interests withdrawn.

According to the depositary, the foregoing information relating to the depositary has been provided to the financial community for informational purposes only and is not intended to serve as a representation, warranty or contract modification of any kind.

The information in this section concerning the depositary and depositary’s book-entry system has been obtained from sources we believe to be reliable, but we take no responsibility for the accuracy thereof. The depositary may change or discontinue the foregoing procedures at any time.

Notices

Notices to holders of the securities will be given by mailing the notices to each holder by first class mail, postage prepaid, at the respective address of each holder as that address appears upon our books. We expect that notices given to the depositary, as holder of the registered global securities, will be passed on to the beneficial owners of the securities in accordance with the standard rules and procedures of the depositary and its direct and indirect participants.

S-24

Table of Contents

UNITED STATES FEDERAL INCOME TAXATION

Set forth in full below is the opinion of Sidley Austin Brown & Wood LLP, counsel to ML&Co. (“Tax Counsel”). As the law applicable to the U.S. federal income taxation of instruments such as the securities is technical and complex, the discussion below necessarily represents only a general summary. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change (including changes in effective dates) or possible differing interpretations. It deals only with securities held as capital assets and does not purport to deal with persons in special tax situations, such as financial institutions, insurance companies, real estate investment trusts, regulated investment companies, tax-exempt entities (except to the extent specifically discussed below), dealers in securities or currencies, persons holding securities as a hedge against currency risks, as a position in a “straddle” or as part of a “hedging,” “conversion” or “integrated” transaction for tax purposes, or persons whose functional currency is not the United States dollar. It also does not deal with holders other than original purchasers (except where otherwise specifically noted). If a partnership holds the securities, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. Thus, persons who are partners in a partnership holding the securities should consult their tax advisors. Moreover, all persons considering the purchase of the securities should consult their own tax advisors concerning the application of U.S. federal income tax laws to their particular situations as well as any consequences of the purchase, ownership and disposition of the securities arising under the laws of any other taxing jurisdiction.

As used herein, the term “U.S. Holder” means a beneficial owner of a security that is for U.S. federal income tax purposes (i) a citizen or resident of the United States, (ii) a corporation or a partnership (including an entity treated as a corporation or a partnership for U.S. federal income tax purposes) that is created or organized in or under the laws of the United States, any state thereof or the District of Columbia (unless, in the case of a partnership, Treasury regulations are adopted that provide otherwise), (iii) an estate whose income is subject to U.S. federal income tax regardless of its source, (iv) a trust if a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons have the authority to control all substantial decisions of the trust or (v) any other person whose income or gain in respect of a security is effectively connected with the conduct of a United States trade or business. Certain trusts not described in clause (iv) above in existence on August 20, 1996, that elect to be treated as United States persons will also be U.S. Holders for purposes of the following discussion. As used herein, the term “non-U.S. Holder” means a beneficial owner of a security that is not a U.S. Holder.

General

There are no statutory provisions, regulations, published rulings or judicial decisions addressing or involving the characterization and treatment, for U.S. federal income tax purposes, of the securities or of securities with terms substantially the same as the securities. Accordingly, the proper U.S. federal income tax characterization and treatment of the securities is uncertain. Pursuant to the terms of the securities, ML&Co. and every holder of a security agree (in the absence of an administrative determination or judicial ruling to the contrary) to characterize each security for all tax purposes as an investment unit consisting of the following components (the “Components”): (i) a debt instrument of ML&Co. (the “Debt Instrument”) with a fixed principal amount unconditionally payable on the maturity date equal to the principal amount of the security and bearing stated interest at the stated interest rate for the security (the “Interest Rate”) and (ii) a contract (the “Forward Contract”) pursuant to which the holder agrees to use the principal payment due on the Debt Instrument to make a payment to ML&Co. on the maturity date in exchange for the right to receive a variable number of shares of Nuveen Stock (subject to ML&Co.’s right to elect cash settlement). In the opinion of Tax Counsel, such characterization and tax treatment of the securities, although not the only reasonable characterization and tax treatment, is based on reasonable interpretations of law currently in effect and, even if successfully challenged by the Internal Revenue Service (the “IRS”), will not result in the imposition of penalties. Furthermore, based on ML&Co.’s determination of the relative fair market values of the Components at the time of issuance of the securities, ML&Co. has assigned $35.44 of the original issue price of the securities to the Debt Instrument and

S-25

Table of Contents

has assigned $1.44 of the original issue price of the securities to the Forward Contract. Based upon the foregoing, a U.S. Holder who acquires a security in connection with the original issuance thereof will be treated as having purchased the Debt Instrument for $35.44 and as having received an initial payment (the “Initial Forward Contract Payment”) with respect to the Forward Contract in an amount equal to $1.44. Except as otherwise described below, the initial payment (or appropriate portion thereof, as more fully described below) deemed to have been received by a U.S. Holder with respect to the Forward Contract (i.e., the Initial Forward Contract Payment) should only be taken into account by the U.S. Holder as an additional amount realized with respect to the Forward Contract upon the sale or other disposition of the securities by the U.S. Holder (including a retirement of the securities prior to the maturity date) or, as described below, on the maturity date or settlement date (which would reduce the U.S. Holder’s tax basis in any shares of Nuveen Stock received thereby or, to the extent cash is received by the U.S. Holder, increase the amount of gain or decrease the amount of loss realized with respect to the Forward Contract). ML&Co.’s allocation of the original issue price will be binding on a U.S. Holder of a security, unless the U.S. Holder timely and explicitly discloses to the IRS that its allocation is different from ML&Co.’s. The treatment of the securities described above and ML&Co.’s allocation are not, however, binding on the IRS or the courts. No statutory, judicial or administrative authority directly addresses the characterization of the securities or instruments similar to the securities for U.S. federal income tax purposes, and no ruling is being requested from the IRS with respect to the securities.

Due to the absence of authorities that directly address instruments that are similar to the securities, significant aspects of the U.S. federal income tax consequences of an investment in the securities are not certain, and no assurance can be given that the IRS or the courts will agree with the characterization described above. Accordingly, prospective purchasers are urged to consult their tax advisors regarding the U.S. federal income tax consequences of an investment in a security (including alternative characterizations of a security) and with respect to any tax consequences arising under the laws of any state, local or foreign taxing jurisdiction. Unless otherwise stated, the following discussions are based on the assumption that the treatment and the allocation described above are accepted for U.S. federal income tax purposes.

Tax Treatment of a security

Interest on the Debt Instrument.    As described above, the Debt Instrument is treated as bearing interest at a stated rate of 6.75% per annum (i.e., the Interest Rate), which is payable quarterly beginning on July 15, 2005. A U.S. Holder will include “qualified stated interest” equal to the stated interest on the security in income in accordance with the U.S. Holder’s regular method of accounting for U.S. federal income tax purposes (subject to the bond premium rules). Based on ML&Co.’s determination set forth above, the U.S. Holder’s tax basis in the Debt Instrument will initially be $35.44.

Settlement of the Forward Contract.    The proper U.S. federal income tax treatment of the receipt of the exchange amount (whether paid in shares of Nuveen Stock or cash) is uncertain. ML&Co. and every holder of a security agree (in the absence of an administrative determination or judicial ruling to the contrary) to take the position that, pursuant to the terms of the Forward Contract, on each valuation date a U.S. Holder will have applied an amount (the “Allocable Forward Contract Payment Amount”) equal to one-thirtieth of an amount equal to the difference between (i) the principal amount of the Debt Instrument and (ii) the Initial Forward Contract Payment toward the purchase of a number of shares of Nuveen Stock equal to the exchange amount for each such valuation date (subject to ML&Co.’s right to elect cash settlement). Under this treatment, the proper method for allocating the Allocable Forward Contract Payment Amount among any shares (including fractional shares) of Nuveen Stock or cash which constitutes the exchange amount relating to any particular valuation date is uncertain. ML&Co. intends to take the position that the Allocable Forward Contract Payment Amount should be allocated among such shares (including fractional shares) of Nuveen Stock or cash based upon the relative fair market value of shares of Nuveen Stock as of the applicable valuation date.

Under this treatment, a U.S. Holder should be treated as having purchased the exchange amount relating to any particular valuation date at the time that the exchange amount is irrevocably delivered to the trustee for the benefit of the holders of the securities, even though the exchange amount will not be delivered to the U.S. Holder

S-26

Table of Contents

until the maturity date. A U.S. Holder should not be required to recognize any gain or loss with respect to any shares of Nuveen Stock received pursuant to the Forward Contract. However, a U.S. Holder should be required to recognize gain or loss with respect to any cash received in lieu of fractional shares of Nuveen Stock. The amount of that gain or loss would be equal to the difference, if any, between the amount of cash received in lieu of fractional shares of Nuveen Stock and the portion of the Allocable Forward Contract Payment Amount that is allocable to those fractional shares of Nuveen Stock (as described above). Any such gain or loss would be treated as short-term capital gain or loss. A U.S. Holder’s tax basis in the shares of Nuveen Stock received thereby should be equal to the portion of the Allocable Forward Contract Payment Amount that is allocable to such shares of Nuveen Stock less the portion of such Allocable Forward Contract Payment Amount that is allocable to any fractional shares of Nuveen Stock (each as described above). A U.S. Holder’s holding period for the shares of Nuveen Stock would begin on the day immediately following the day on which the exchange amount is irrevocably delivered to the trustee for the benefit of the holders of the securities. Alternatively, pursuant to this agreed upon treatment, to the extent that a U.S. Holder receives cash (other than cash in lieu of fractional shares of Nuveen Stock, as described above, and other than payments of interest on the securities), ML&Co. and every holder of a security agree to treat the receipt of such cash as a taxable event. Under this treatment, a U.S. Holder should be required to recognize gain or loss in an amount equal to the difference, if any, between the amount of cash received by the U.S. Holder and the portion of the Allocable Forward Contract Payment Amount that is allocable to such cash (as described above). Moreover, pursuant to this agreed upon treatment, ML&Co. and every holder of a security agree to treat any such gain or loss as long-term or short-term capital gain or loss (depending upon the U.S. Holder’s holding period for the security). The deductibility of capital losses is subject to certain limitations.

Sale, Exchange or Early Retirement of the securities

Upon a sale or exchange of a security prior to the maturity date of the securities, or upon the retirement of a security prior to the maturity date upon the occurrence of an event of default acceleration or a reorganization event acceleration, a U.S. Holder would recognize taxable gain or loss equal to the difference between (or the sum of) the amount realized on that sale, exchange or retirement (as allocated among the Components in accordance with their relative fair market values) and such U.S. Holder’s tax basis in the Components deemed so sold, exchanged or retired. Any such gain or loss would generally be long-term or short-term capital gain or loss (depending on the U.S. Holder’s holding period for the security). Based upon the treatment of the securities described above, if a U.S. Holder sells, exchanges or otherwise disposes of a security prior to the maturity date and subsequent to any date on which exchange property has been irrevocably delivered to the trustee for the benefit of the holders of the securities, the U.S. Holder should be treated as having also sold, exchanged or otherwise disposed of the exchange amount so previously delivered to the trustee. In such event, a U.S. Holder’s initial “negative” tax basis (i.e., the Initial Forward Contract Payment) would be increased by the portion of any Allocable Forward Contract Payment Amount that was previously allocated to the exchange amount previously delivered to the trustee. To the extent that a U.S. Holder recognizes gain or loss in respect of any shares of Nuveen Stock deemed to have been sold or exchanged upon the sale or exchange of a security, such gain or loss will be short-term capital gain or loss. For these purposes, the amount realized does not include any amount attributable to accrued interest on the Debt Instrument, which would be taxed as described under “Tax Treatment of a security—Interest on the Debt Instrument” above.

Delivery of Nuveen Stock to Trustee Prior to any Valuation Date

The discussion above assumes that there is no irrevocable delivery of Nuveen Stock to the trustee prior to any valuation date for the benefit of the holders of the securities. In the event that an irrevocable delivery of Nuveen Stock is made to the trustee for the benefit of the holders of the securities prior to any valuation date, ML&Co. intends to take the position that the U.S. Holder of the security will be treated, for U.S. federal income tax purposes, as having received and owned the Nuveen Stock once the Nuveen Stock is delivered to the trustee even though such Nuveen Stock and any income thereon (including dividends) will not be delivered to the holder by the trustee until the maturity date. Thus, in such event, the U.S. Holder would be taxed on any dividends paid on such shares of Nuveen Stock at the time such dividends are paid on such shares of Nuveen Stock. The U.S.

S-27

Table of Contents

Holder, however, would not recognize any gain or loss with respect to the receipt by the trustee of the Nuveen Stock. U.S. Holders should consult their own tax advisors regarding the tax consequences of such event (including the amount of tax basis allocable to Nuveen Stock and the effect of such event on the sale or exchange of the securities).

Premium

If a U.S. Holder purchases the Debt Instrument for an amount that is greater than the sum of all amounts payable on the Debt Instrument after the purchase date other than payments of qualified stated interest (i.e., the principal amount), a U.S. Holder will be considered to have purchased the Debt Instrument with “amortizable bond premium” equal in amount to that excess. A U.S. Holder may elect to amortize that premium using a constant yield method over the remaining term of the Debt Instrument and may offset interest otherwise required to be included in respect of the Debt Instrument during any taxable year by the amortized amount of that excess for the taxable year. U.S. Holders are urged to consult their own tax advisors regarding the application of these special rules. Any election to amortize bond premium applies to all taxable debt instruments acquired by the U.S. Holder on or after the first day of the first taxable year to which that election applies and may be revoked only with the consent of the IRS.

Possible Alternative Tax Treatments of an Investment in a security

Due to the absence of authorities that directly address the proper characterization of the securities, no assurance can be given that the IRS will accept, or that a court will uphold, the characterization and tax treatment described above. In particular, the IRS could seek to analyze the U.S. federal income tax consequences of owning a security under Treasury regulations governing contingent payment debt instruments (the “CPDI Regulations”).

ML&Co. will take the position that the CPDI Regulations do not apply to the securities. If the IRS were successful in asserting that the CPDI Regulations applied to the securities, the timing and character of income thereon would be significantly affected. Among other things, a U.S. Holder would be required to accrue as original issue discount, subject to the adjustments described below, income at a “comparable yield” on the issue price, regardless of the U.S. Holder’s usual method of accounting for U.S. federal income tax purposes. In addition, the CPDI Regulations require that a projected payment schedule, which results in such a “comparable yield,” be determined, and that adjustments to income accruals be made to account for differences between actual payments and projected amounts (including upon receipt of the shares of Nuveen Stock on the maturity date). Furthermore, any gain realized with respect to a security (including any gain attributable to the value of shares of Nuveen Stock received on the maturity date) would generally be treated as ordinary income, and any loss realized would generally be treated as ordinary loss to the extent of the U.S. Holder’s prior ordinary income inclusions (which were not previously reversed) with respect to the security.

Even if the CPDI Regulations do not apply to the securities, other alternative U.S. federal income tax characterizations or treatments of the securities are also possible, which may also affect the timing and the character of the income or loss with respect to the securities. Accordingly, prospective purchasers are urged to consult their tax advisors regarding the U.S. federal income tax consequences of an investment in a security.

Constructive Ownership Law

Section 1260 of the Internal Revenue Code of 1986, as amended (the “Code”) treats a taxpayer owning certain types of derivative positions in property as having “constructive ownership” of that property, with the result that all or a portion of any long-term capital gain recognized by such taxpayer with respect to the derivative position will be recharacterized as ordinary income. In its current form, Section 1260 of the Code does not apply to the securities. If Section 1260 of the Code were to apply to the securities in the future, however, the effect on a U.S. Holder of a security would be to treat all or a portion of any long-term capital gain recognized by such U.S. Holder on the sale, exchange, retirement or maturity of a security (or upon the sale of any shares of Nuveen Stock received thereon) as ordinary income. In addition, Section 1260 of the Code would impose an

S-28

Table of Contents

interest charge on any such gain that was recharacterized. U.S. Holders should consult their tax advisors regarding the potential application of Section 1260 of the Code, if any, to the purchase, ownership and disposition of a security.

Unrelated Business Taxable Income

Section 511 of the Code generally imposes a tax, at regular corporate or trust income tax rates, on the “unrelated business taxable income” of certain tax-exempt organizations, including qualified pension and profit sharing plan trusts and individual retirement accounts. As discussed above, the U.S. federal income tax characterization of the securities is uncertain. Nevertheless, in general, if the securities are held for investment purposes, the amount of income or gain, if any, realized over the term of the securities, on the maturity date or upon a sale, exchange or retirement of a security prior to the maturity date, or any income that would accrue to a holder of a security if the securities were characterized as contingent payment debt instruments (as discussed above), will not constitute unrelated business taxable income. However, if a security constitutes debt-financed property (as defined in Section 514(b) of the Code) by reason of indebtedness incurred by a holder of a security to purchase the security, all or a portion of any income or gain realized with respect to such security may be classified as unrelated business taxable income pursuant to Section 514 of the Code. Moreover, prospective investors in the securities should be aware that whether or not any income or gain realized with respect to a security which is owned by an organization that is generally exempt from U.S. federal income taxation pursuant to Section 501(a) of the Code constitutes unrelated business taxable income will depend upon the specific facts and circumstances applicable to such organization. Accordingly, any potential investors in the securities that are generally exempt from U.S. federal income taxation pursuant to Section 501(a) of the Code are urged to consult with their own tax advisors concerning the U.S. federal income tax consequences to them of investing in the securities.

Non-U.S. Holders

In the case of a non-U.S. Holder, ML&Co. intends to withhold applicable United States withholding taxes at a rate of 30% on payments of interest made with respect to the securities subject to reduction by applicable treaty or upon the receipt of a Form W-8ECI from a non-U.S. Holder claiming that the payments are effectively connected with the conduct of a United States trade or business. Any capital gain realized upon the sale or other disposition of a security by a non-U.S. Holder will generally not be subject to U.S. federal income tax if (i) that gain is not effectively connected with a United States trade or business of that non-U.S. Holder and (ii) in the case of an individual non-U.S. Holder, that individual is not present in the United States for 183 days or more in the taxable year of the sale or other disposition and that individual does not have a “tax home” (as defined for U.S. federal income tax purposes) in the United States.

As discussed above, ML&Co. intends to take the position that a holder of a security will be treated for U.S. federal income tax purposes, as having received and owned any shares of Nuveen Stock once the shares of Nuveen Stock are irrevocably delivered to the trustee for the benefit of the holders of the securities, even though the shares of Nuveen Stock (and the income thereon) will not be delivered to the holder by the trustee until the maturity date. Accordingly, if dividends are paid on the shares of Nuveen Stock that are deemed to be held by a Non-U.S. Holder, such dividends will be subject to applicable United States withholding taxes.

Backup Withholding and Information Reporting

A beneficial owner of a security may be subject to information reporting with respect to certain amounts paid to the beneficial owner. A beneficial owner of a security may also be subject to backup withholding at the applicable statutory rate of U.S. federal income tax on certain amounts paid to the beneficial owner unless such beneficial owner provides proof of an applicable exemption or a correct taxpayer identification number, and otherwise complies with applicable requirements of the backup withholding rules. Any amounts withheld under the backup withholding rules from a payment to a beneficial owner would be allowed as a refund or a credit against such beneficial owner’s U.S. federal income tax provided the required information is furnished to the IRS.

S-29

Table of Contents

ERISA MATTERS

Each fiduciary of a pension, profit-sharing or other employee benefit plan subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) (a “Plan”), should consider the fiduciary standards of ERISA in the context of the Plan’s particular circumstances before authorizing an investment in the securities. Accordingly, among other factors, the fiduciary should consider whether the investment would satisfy the prudence and diversification requirements of ERISA and would be consistent with the documents and instruments governing the Plan.

In addition, we and certain of our subsidiaries and affiliates, including MLPF&S, may be each considered a party in interest within the meaning of ERISA, or a disqualified person within the meaning of the Internal Revenue Code of 1986, as amended (the “Code”), with respect to many Plans, as well as many individual retirement accounts and Keogh plans (also Plans ). Prohibited transactions within the meaning of ERISA or the Code would likely arise, for example, if the securities are acquired by or with the assets of a Plan with respect to which MLPF&S or any of their affiliates is a service provider or other party in interest, unless the securities are acquired pursuant to an exemption from the prohibited transaction rules. A violation of these prohibited transaction rules could result in an excise tax or other liabilities under ERISA and/or Section 4975 of the Code for such persons, unless exemptive relief is available under an applicable statutory or administrative exemption.

The U.S. Department of Labor has issued five prohibited transaction class exemptions (“PTCEs”) that may provide exemptive relief for direct or indirect prohibited transactions resulting from the purchase or holding of the securities. Those class exemptions are PTCE 96-23 (for certain transactions determined by in-house asset managers), PTCE 95-60 (for certain transactions involving insurance company general accounts), PTCE 91-38 (for certain transactions involving bank collective investment funds), PTCE 90-1 (for certain transactions involving insurance company separate accounts), and PTCE 84-14 (for certain transactions determined by independent qualified asset managers).

Because we may be considered a party in interest with respect to many Plans, the securities may not be purchased, held or disposed of by any Plan, any entity whose underlying assets include plan assets by reason of any Plan’s investment in the entity (a Plan Asset Entity ) or any person investing plan assets of any Plan, unless such purchase, holding or disposition is eligible for exemptive relief, including relief available under PTCE 96-23, 95-60, 91-38, 90-1, or 84-14 or such purchase, holding or disposition is otherwise not prohibited. Any purchaser, including any fiduciary purchasing on behalf of a Plan, transferee or holder of the securities will be deemed to have represented, in its corporate and its fiduciary capacity, by its purchase and holding of the securities that either (a) it is not a Plan or a Plan Asset Entity and is not purchasing such securities on behalf of or with plan assets of any Plan or with any assets of a governmental or church plan that is subject to any federal, state or local law that is substantially similar to the provisions of Section 406 of ERISA or Section 4975 of the Code or (b) its purchase, holding and disposition are eligible for exemptive relief or such purchase, holding and disposition are not prohibited by ERISA or Section 4975 of the Code (or in the case of a governmental or church plan, any substantially similar federal, state or local law).

Under ERISA, assets of a Plan may include assets held in the general account of an insurance company which has issued an insurance policy to such plan or assets of an entity in which the Plan has invested. Accordingly, insurance company general accounts that include assets of a Plan must ensure that one of the foregoing exemptions is available. Due to the complexity of these rules and the penalties that may be imposed upon persons involved in non-exempt prohibited transactions, it is particularly important that fiduciaries or other persons considering purchasing the securities on behalf of or with “plan assets” of any Plan consult with their counsel regarding the availability of exemptive relief under PTCEs 96-23, 95-60, 91-38, 90-1 or 84-14.

In addition to considering the consequences of holding the securities, employee benefit plans subject to ERISA or insurance companies deemed to be investing ERISA plan assets (or other governmental or church plans subject to similar regulation, as described above) purchasing the securities should also consider the possible implications of owning Nuveen Stock upon exchange of the securities at maturity. Purchasers of the securities have exclusive responsibility for ensuring that their purchase, holding and disposition of the securities do not violate the prohibited transaction rules of ERISA or the Code or any similar regulations applicable to governmental or church plans, as described above.

S-30

Table of Contents

PLAN OF DISTRIBUTION

This prospectus supplement and the accompanying prospectus are being used by MLPF&S and its affiliates in connection with offers and sales of the securities in market-making transactions effected from time to time. MLPF&S and its affiliates may act as a principal or agent in such transactions, including as agent for the counterparty when acting as principal or as agent for both counterparties, and may receive compensation in the form of discounts and commissions, including from both counterparties when it acts as agent for both.

MLPF&S has informed us that it does not intend to confirm sales of the securities to any accounts over which it exercises discretionary authority without the prior specific written approval of those transactions by the customer.

We have been advised by MLPF&S that, subject to applicable laws and regulations, MLPF&S currently intends to make a market in the securities. However, MLPF&S is not obligated to do so and any market-making may be interrupted or discontinued at any time without notice. In addition, that market-making activity will be subject to the limits imposed by the Securities Act of 1933 and the Securities Exchange Act of 1934. There can be no assurance that an active trading market will develop or be sustained.

VALIDITY OF SECURITIES

The validity of the securities has been passed upon for ML&Co. by Sidley Austin Brown & Wood LLP.

EXPERTS

The consolidated financial statements, the related financial statement schedule, and management’s report on the effectiveness of internal control over financial reporting incorporated in this prospectus by reference from the Annual Report on Form 10-K of Merrill Lynch & Co., Inc. for the year ended December 31, 2004, have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their reports dated March 2, 2005, which reports (1) express an unqualified opinion on the financial statement and financial statement schedule, (2) express an unqualified opinion on management’s assessment regarding the effectiveness of internal control over financial reporting, and (3) express an unqualified opinion on the effectiveness of internal control over financial reporting, and have been so incorporated in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.

S-31

Table of Contents

WHERE YOU CAN FIND MORE INFORMATION

ML&Co.

We file reports, proxy statements and other information with the SEC. Our SEC filings are also available over the Internet at the SEC’s web site at http://www.sec.gov. The address of the SEC’s Internet site is provided solely for the information of prospective investors and is not intended to be an active link. You may also read and copy any document we file by visiting the SEC’s public reference room in Washington, D.C. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room and their copy charges. You may also inspect our SEC reports and other information at the New York Stock Exchange, Inc., 20 Broad Street, New York, New York 10005.

We have filed a registration statement on Form S-3 with the SEC covering the securities which are referred to as STRYPES and other securities. For further information on ML&Co. and the securities, you should refer to our registration statement and its exhibits. The prospectus of ML&Co. accompanying this prospectus supplement summarizes material provisions of contracts and other documents that we refer you to. Because the prospectus may not contain all the information that you may find important, you should review the full text of these documents. We have included copies of these documents as exhibits to our registration statement.

You should rely only on the information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus of ML&Co.. We have not, and the underwriter has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the underwriter is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted.

You should assume that the information appearing in this prospectus supplement and the accompanying prospectus is accurate as of the date on the front cover of this prospectus supplement only. Our business, financial condition and results of operations may have changed since that date.

Nuveen Investments, Inc.

Nuveen is required to file certain information with the SEC pursuant to the Exchange Act, which information can be located at the SEC’s facilities or accessed through the SEC’s web site by reference to SEC file number 001-11123. You may also inspect Nuveen’s SEC reports and other information at the NYSE. In addition, information regarding Nuveen may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents. We make no representation or warranty as to the accuracy or completeness of the information or reports.

S-32

Table of Contents

$275,060,000

Merrill Lynch & Co., Inc.

6.75% Mandatorily Exchangeable Securities due October 15, 2007

Mandatorily Exchangeable for

Shares of Class A Common Stock of NUVEEN INVESTMENTS, INC.

Merrill Lynch & Co.

May 3, 2005